Detalhe da pesquisa
1.
A CD25-biased interleukin-2 for autoimmune therapy engineered via a semi-synthetic organism.
Commun Med (Lond)
; 4(1): 58, 2024 Mar 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38532017
2.
Smart drugs: tyrosine kinase inhibitors in cancer therapy.
Cancer Cell
; 1(2): 117-23, 2002 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-12086869
3.
An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism.
Nat Commun
; 12(1): 4785, 2021 08 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34373459
4.
CB-6644 Is a Selective Inhibitor of the RUVBL1/2 Complex with Anticancer Activity.
ACS Chem Biol
; 14(2): 236-244, 2019 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30640450
5.
The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.
Mol Cancer Ther
; 16(11): 2375-2386, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28878026
6.
Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083).
J Med Chem
; 58(24): 9480-97, 2015 Dec 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-26565666
7.
Targeting the AAA ATPase p97 as an Approach to Treat Cancer through Disruption of Protein Homeostasis.
Cancer Cell
; 28(5): 653-665, 2015 Nov 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-26555175
8.
Application of LC/MS/MS in the quantitation of SU101 and SU0020 uptake by 3T3/PDGFr cells.
J Pharm Biomed Anal
; 28(3-4): 701-9, 2002 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12008150
9.
Treatment-related protein biomarker expression differs between primary and recurrent ovarian carcinomas.
Mol Cancer Ther
; 11(2): 492-502, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22203729